FDA rejects Capricor Duchenne therapy, a decision that was slow in coming

Adam Feuerstein is a senior biotechnology writer and columnist, reporting on the intersection of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotechnology podcast The Readout Loud and author of the Adam’s Biotech Scorecard newsletter. You can reach Adam on Signal at stataf.54.

The Food and Drug Administration announced Friday that it has rejected a cell therapy for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

The decision to prevent the treatment, called deramiocel, from marketing should have been an easy one for regulators to make. The targeted patient population – adolescents and young men with Duchenne who had already lost the ability to walk – have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to demonstrate that deramiocel could prevent heart failure or preserve muscle function in their arms.

But nothing is simple when it comes to regulating medications for Duchenne, a progressive disease that causes muscle wasting.

Exclusive STAT+ story

STAT+

This article is reserved for STAT+ subscribers

Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.

Already have an account? Log in

See all packages

To read the rest of this story, subscribe to STAT+.

Subscribe

Gn bussni

Logo